^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KSQ-004EX

    i
    Other names: KSQ-004EX, KSQ-004, KSQ004EX, KSQ 004EX, KSQ004, KSQ 004
    Associations

    News

    Trials
    Company:
    KSQ Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    26d
    A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=141, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Nov 2024
    Enrollment open • Trial initiation date • Metastases
    |
    cyclophosphamide • fludarabine IV • KSQ-004EX
    3ms
    A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=141, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial • Metastases
    |
    cyclophosphamide • fludarabine IV • KSQ-004EX
    3years
    KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors (SITC 2021)
    Conclusions We used a novel CRISPR^2 screen approach to identify Regnase-1/SOCS1 as the top dual edit combination enhancing T cell function in the tumor microenvironment. We translated these findings to therapeutic use with the discovery of KSQ-004, a dual-edited eTIL therapy engineered that possesses enhanced anti-tumor potency and persistence against solid tumors.
    Preclinical
    |
    IFNG (Interferon, gamma) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    KSQ-004EX